HighVista Strategies sold 69,092 shares of Structure Therapeutics (NASDAQ:GPCR) in the first quarter, an estimated $4.73 million trade based on quarterly average pricing, per the May 15, 2026 SEC filing.
What happened According to an SEC filing dated May 15, 2026, HighVista Strategies reduced its holding in Structure Therapeutics by 69,092 shares during the first quarter
The estimated transaction value was $4.73 million, calculated using the average closing price for the quarter. The position’s quarter-end value decreased by $7.45 million, a figure that incorporates both the share sale and market price fluctuations. What else to know – This was a sell; post-trade, the Structure Therapeutics stake represents 1.6491% of HighVista’s reportable U.S. equity AUM – Top holdings after the filing: – NYSEMKT:DBC: $30.61 million (8.5% of AUM) – NASDAQ:ABVX: $12.61 million (3.5% of AUM) – NASDAQ:PRAX: $8.48 million (2.3% of AUM) – NASDAQ:COGT: $7.58 million (2.1% of AUM) – NASDAQ:SYRE: $7.38 million (2.0% of AUM) – – As of May 14, 2026, shares of Structure Therapeutics were priced at $39.84, up about 60% over the past year and well outperforming the S&P 500’s roughly 25% gain in the same period.
Company Overview Company Snapshot – Structure Therapeutics develops oral therapeutics targeting chronic diseases, with lead candidate GSBR-1290 for type-2 diabetes and obesity, and additional pipeline assets for pulmonary and cardiovascular indications. – The company operates a clinical-stage biopharmaceutical business model focused on proprietary research, development, and out-licensing or commercialization of novel small molecule drugs targeting G-protein-coupled receptors (GPCRs). – It targets healthcare providers, biopharma partners, and patients with unmet medical needs in metabolic, pulmonary, and cardiovascular disease segments. Structure Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of innovative oral small molecule therapeutics…